These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 23369185)
21. 3-Nitro-naphthalimide and nitrogen mustard conjugate NNM-25 induces hepatocellular carcinoma apoptosis via PARP-1/p53 pathway. Xie SQ; Zhang YH; Li Q; Xu FH; Miao JW; Zhao J; Wang CJ Apoptosis; 2012 Jul; 17(7):725-34. PubMed ID: 22395446 [TBL] [Abstract][Full Text] [Related]
22. Development of novel naphthalimide derivatives and their evaluation as potential melanoma therapeutics. Sk UH; Prakasha Gowda AS; Crampsie MA; Yun JK; Spratt TE; Amin S; Sharma AK Eur J Med Chem; 2011 Aug; 46(8):3331-8. PubMed ID: 21609852 [TBL] [Abstract][Full Text] [Related]
23. Recent developments on 1,8-Naphthalimide moiety as potential target for anticancer agents. Tandon R; Luxami V; Tandon N; Paul K Bioorg Chem; 2022 Apr; 121():105677. PubMed ID: 35202852 [TBL] [Abstract][Full Text] [Related]
24. Unprecedented synthesis, in vitro and in vivo anti-cancer evaluation of novel triazolonaphthalimide derivatives. Li S; Zhong W; Li Z; Meng X Eur J Med Chem; 2012 Jan; 47(1):546-52. PubMed ID: 22138307 [TBL] [Abstract][Full Text] [Related]
25. Effect of intercalator substituent and nucleotide sequence on the stability of DNA- and RNA-naphthalimide complexes. Johnson CA; Hudson GA; Hardebeck LK; Jolley EA; Ren Y; Lewis M; Znosko BM Bioorg Med Chem; 2015 Jul; 23(13):3586-91. PubMed ID: 25960324 [TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis, and Evaluation of Novel 3-Carboranyl-1,8-Naphthalimide Derivatives as Potential Anticancer Agents. Rykowski S; Gurda-Woźna D; Orlicka-Płocka M; Fedoruk-Wyszomirska A; Giel-Pietraszuk M; Wyszko E; Kowalczyk A; Stączek P; Bak A; Kiliszek A; Rypniewski W; Olejniczak AB Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803403 [TBL] [Abstract][Full Text] [Related]
28. Bis-naphthalimides: a new class of antitumor agents. Braña MF; Castellano JM; Morán M; Pérez de Vega MJ; Romerdahl CR; Qian XD; Bousquet P; Emling F; Schlick E; Keilhauer G Anticancer Drug Des; 1993 Aug; 8(4):257-68. PubMed ID: 8240655 [TBL] [Abstract][Full Text] [Related]
29. Therapeutic potential of benzothiazoles: a patent review (2010 - 2014). Kamal A; Syed MA; Mohammed SM Expert Opin Ther Pat; 2015 Mar; 25(3):335-49. PubMed ID: 25579497 [TBL] [Abstract][Full Text] [Related]
30. Novel thiazonaphthalimides as efficient antitumor and DNA photocleaving agents: effects of intercalation, side chains, and substituent groups. Li Z; Yang Q; Qian X Bioorg Med Chem; 2005 Aug; 13(16):4864-70. PubMed ID: 15925513 [TBL] [Abstract][Full Text] [Related]
31. Overview of naphthalimide analogs as anticancer agents. Lv M; Xu H Curr Med Chem; 2009; 16(36):4797-813. PubMed ID: 19929786 [TBL] [Abstract][Full Text] [Related]
32. Synthesis of naphthalimide-carborane and metallacarborane conjugates: Anticancer activity, DNA binding ability. Nekvinda J; Różycka D; Rykowski S; Wyszko E; Fedoruk-Wyszomirska A; Gurda D; Orlicka-Płocka M; Giel-Pietraszuk M; Kiliszek A; Rypniewski W; Bachorz R; Wojcieszak J; Grüner B; Olejniczak AB Bioorg Chem; 2020 Jan; 94():103432. PubMed ID: 31776032 [TBL] [Abstract][Full Text] [Related]
33. DNA binding and anticancer activity of naphthalimides with 4-hydroxyl-alkylamine side chains at different lengths. Wang K; Wang Y; Yan X; Chen H; Ma G; Zhang P; Li J; Li X; Zhang J Bioorg Med Chem Lett; 2012 Jan; 22(2):937-41. PubMed ID: 22200595 [TBL] [Abstract][Full Text] [Related]
34. Recent advances on structural modifications of benzothiazoles and their conjugate systems as potential chemotherapeutics. Ahmed K; Yellamelli Valli Venkata S; Mohammed NA; Sultana F; Methuku KR Expert Opin Investig Drugs; 2012 May; 21(5):619-35. PubMed ID: 22493977 [TBL] [Abstract][Full Text] [Related]
35. Research Progress on Structure-Activity Relationship of 1,8-Naphthalimide DNA Chimeras Against Tumor. Zhang HY; Han LL; Wu HY; Xu XX; Yu MB; Chen GY; Qi XL Technol Cancer Res Treat; 2024; 23():15330338231225861. PubMed ID: 38225189 [TBL] [Abstract][Full Text] [Related]
37. A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis. Chen Z; Liang X; Zhang H; Xie H; Liu J; Xu Y; Zhu W; Wang Y; Wang X; Tan S; Kuang D; Qian X J Med Chem; 2010 Mar; 53(6):2589-600. PubMed ID: 20170164 [TBL] [Abstract][Full Text] [Related]
38. Synthesis, in vitro evaluation and molecular modelling of naphthalimide analogue as anticancer agents. Verma M; Luxami V; Paul K Eur J Med Chem; 2013 Oct; 68():352-60. PubMed ID: 23994328 [TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs. Antonini I; Volpini R; Dal Ben D; Lambertucci C; Cristalli G Bioorg Med Chem; 2008 Sep; 16(18):8440-6. PubMed ID: 18774722 [TBL] [Abstract][Full Text] [Related]
40. Design, Synthesis and Antimicrobial Evaluation of Novel Benzimidazoleincorporated Naphthalimide Derivatives as Ning ZW; Zhang HZ; Zhou CH Med Chem; 2022; 18(5):544-557. PubMed ID: 34254924 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]